1. Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses
- Author
-
Duncan G. Ithinji, David W. Buchholz, Shahrzad Ezzatpour, I. Abrrey Monreal, Yu Cong, Julie Sahler, Amandip Singh Bangar, Brian Imbiakha, Viraj Upadhye, Janie Liang, Andrew Ma, Birgit Bradel-Tretheway, Benjamin Kaza, Yao Yu Yeo, Eun Jin Choi, Gunner P. Johnston, Louis Huzella, Erin Kollins, Saurabh Dixit, Shuiqing Yu, Elena Postnikova, Victoria Ortega, Avery August, Michael R. Holbrook, and Hector C. Aguilar
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Experimental vaccines for the deadly zoonotic Nipah (NiV), Hendra (HeV), and Ebola (EBOV) viruses have focused on targeting individual viruses, although their geographical and bat reservoir host overlaps warrant creation of multivalent vaccines. Here we explored whether replication-incompetent pseudotyped vesicular stomatitis virus (VSV) virions or NiV-based virus-like particles (VLPs) were suitable multivalent vaccine platforms by co-incorporating multiple surface glycoproteins from NiV, HeV, and EBOV onto these virions. We then enhanced the vaccines’ thermotolerance using carbohydrates to enhance applicability in global regions that lack cold-chain infrastructure. Excitingly, in a Syrian hamster model of disease, the VSV multivalent vaccine elicited safe, strong, and protective neutralizing antibody responses against challenge with NiV, HeV, or EBOV. Our study provides proof-of-principle evidence that replication-incompetent multivalent viral particle vaccines are sufficient to provide protection against multiple zoonotic deadly viruses with high pandemic potential.
- Published
- 2022
- Full Text
- View/download PDF